SCHEMBL802068

SCHEMBL802068

Cc1ccccc1-c1cc(Nc2n[nH]c3ccccc23)cc(C2CCNCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 2/20 0.41
TRPA1 O75762 1/20 0.40
ULK1 O75385 2/20 0.40
CYP1A2 P05177 2/20 0.40
HSD17B10 Q99714 1/20 0.40
GRM4 Q14833 4/20 0.40
ADRA2A P08913 2/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
ACP1 P24666 1/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
KMT2A Q03164 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
PLAT P00750 1/20 0.35
BRD4 O60885 1/20 0.35
ATAD2 Q6PL18 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802064 0.91 GSK3A (0.42) FADS1TRPA1CYP1A2GRM4ADRA2A
SCHEMBL12619886 0.85 CYP1A2 (0.43) FADS1TRPA1ULK1CYP1A2GRM4
SCHEMBL802027 0.82 FADS1 (0.46) FADS1TRPA1CYP1A2HSD17B10GRM4
SCHEMBL802326 0.82 FADS1 (0.48) FADS1TRPA1CYP1A2HSD17B10GRM4
SCHEMBL801685 0.81 GSK3B (0.47) FADS1TRPA1CYP1A2CYP3A4CYP2D6
SCHEMBL802687 0.81 PAK4 (0.43) CYP1A2CYP3A4CYP2D6GABRA1GABRB2
SCHEMBL802710 0.79 GSK3A (0.42) FADS1TRPA1GRM4ADRA2AACP1
SCHEMBL802516 0.79 NPC1 (0.38) CYP1A2HSD17B10ACP1MEN1CYP3A4
SCHEMBL12619882 0.77 USP1 (0.43) FADS1TRPA1CYP1A2HSD17B10GRM4
SCHEMBL802674 0.74 GSK3A (0.44) FADS1TRPA1CYP1A2GRM4ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7473691-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 FADS1 3442/4885TRPA1 4786/4885ULK1 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.